|
CA3087392A1
|
|
Crystalline forms of niraparib tosylate
|
|
CA3077296A1
|
|
Novel crystalline form betrixaban maleate
|
|
CA3067611A1
|
|
Processes for the preparation of tezacaftor and intermediates thereof
|
|
US2020207761A1
|
|
Crystalline Form of Valbenazine Dibesylate
|
|
CA3048036A1
|
|
Novel crystalline form of ribociclib succinate
|
|
US2019390235A1
|
|
Processes for the Preparation of Dasotraline and Intermediates Thereof
|
|
US2019343815A1
|
|
Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US2019345163A1
|
|
Processes for the preparation of Ribociclib and intermediates thereof
|
|
US2019330150A1
|
|
Processes for the Preparation of 3-(4-Halobutyl)-5-Cyanoindole
|
|
US2019276424A1
|
|
Processes for the preparation of apalutamide and intermediates thereof
|
|
CA3031777A1
|
|
Crystalline form of olaparib
|
|
US2019194122A1
|
|
Processes for the Preparation of Dasotraline and Intermediates Thereof
|
|
US2019144397A1
|
|
Crystalline form of selexipag
|
|
CA3021507A1
|
|
Processes for the preparation of veliparib and intermediates thereof
|
|
CA3020592A1
|
|
Novel crystalline form of lumacaftor
|
|
CA3018321A1
|
|
Novel crystalline form of eluxadoline
|
|
CA3073293A1
|
|
Novel crystalline forms of acalabrutinib
|
|
CA3067271A1
|
|
Crystalline forms of ponatinib hydrochloride
|
|
EP3575300A1
|
|
Novel crystalline forms of ibrutinib
|
|
CN110540539A
|
|
Novel crystal form of ibrutinib
|
